BCMA CHO Recombinant Cell Line (High Expression)

BCMA CHO Recombinant Cell Line (High Expression)
Artikelnummer
BPS79500-H
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience

Verfügbarkeit: wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€

Background: B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. CART-BCMA is an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR (chimeric antigen receptor). CAR T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.

Description: Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry.

Genbank: NM_001192

Host Cell Line: CHO

Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Storage Stability: Immediately upon receipt, store vials in liquid nitrogen

Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-1

References: 1. Ghosh A, et al. CAR T cell therapy for multiple myeloma Leuk Lymphoma. 2017 Nov; 6:1-12.2. Sanchez E, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Mar; 7:1-11.3. Sohail A., et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018 Feb 1; 10(4):265-282.4. Sidaway P., et al. Anti-BCMA CAR T cells show promise in MM. Nat Rev Clin Oncol. 2016 Sep;13(9):530.
Mehr Informationen
Artikelnummer BPS79500-H
Hersteller BPS Bioscience
Hersteller Artikelnummer 79500-H
Green Labware Nein
Verpackungseinheit 2 vials
Mengeneinheit PAK
Wirt Hamster
Produktinformation (PDF) Download
MSDS (PDF)
×